These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 27801326

  • 1. [Study of abnormal iron metabolism parameters and iron overload in patients with myelodysplastic syndromes].
    Song LL, Zheng QQ, Xiao C, Guo J, Wu D, Su JY, Zhou LY, Chang CK.
    Zhonghua Xue Ye Xue Za Zhi; 2016 Oct 14; 37(10):903-907. PubMed ID: 27801326
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Study of iron overload assessment by T2* magnetic resonance imaging in patients with myelodysplastic syndromes].
    Song LL, Lu HY, Xiao C, Wu LY, Wu D, Su JY, Zhou LY, Chang CK.
    Zhonghua Xue Ye Xue Za Zhi; 2019 Mar 14; 40(3):222-226. PubMed ID: 30929390
    [Abstract] [Full Text] [Related]

  • 4. Serum iron metabolism and erythropoiesis in patients with myelodysplastic syndrome not receiving RBC transfusions.
    Cui R, Gale RP, Zhu G, Xu Z, Qin T, Zhang Y, Huang G, Li B, Fang L, Zhang H, Pan L, Hu N, Qu S, Xiao Z.
    Leuk Res; 2014 May 14; 38(5):545-50. PubMed ID: 24598841
    [Abstract] [Full Text] [Related]

  • 5. [Study on HFE gene mutations in patients with myelodysplastic syndromes and aplastic anemia].
    Nie L, Ai XF, Zheng YZ, Li QH, Yang L, Xiao ZJ.
    Zhonghua Xue Ye Xue Za Zhi; 2009 Apr 14; 30(4):223-8. PubMed ID: 19731820
    [Abstract] [Full Text] [Related]

  • 6. Cardiac iron overload in chronically transfused patients with thalassemia, sickle cell anemia, or myelodysplastic syndrome.
    de Montalembert M, Ribeil JA, Brousse V, Guerci-Bresler A, Stamatoullas A, Vannier JP, Dumesnil C, Lahary A, Touati M, Bouabdallah K, Cavazzana M, Chauzit E, Baptiste A, Lefebvre T, Puy H, Elie C, Karim Z, Ernst O, Rose C.
    PLoS One; 2017 Apr 14; 12(3):e0172147. PubMed ID: 28257476
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Impact of iron overload by transfusion on survival and leukemia transformation of myelodysplastic syndromes in a single center of China.
    Wang Y, Huang L, Hua Y, Liu H, Jiang H, Wang H, Zhang W, Fu R, Shao Z.
    Hematology; 2021 Dec 14; 26(1):874-880. PubMed ID: 34753406
    [Abstract] [Full Text] [Related]

  • 9. [Iron chelation therapy and its influence on the alleviation of EPO resistance in MDS patients].
    Zhang Y, Xiao C, Gu SC, Chang CK.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Aug 14; 22(4):1027-32. PubMed ID: 25130822
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
    Nolte F, Höchsmann B, Giagounidis A, Lübbert M, Platzbecker U, Haase D, Lück A, Gattermann N, Taupitz M, Baier M, Leismann O, Junkes A, Schumann C, Hofmann WK, Schrezenmeier H.
    Ann Hematol; 2013 Jan 14; 92(2):191-8. PubMed ID: 23073603
    [Abstract] [Full Text] [Related]

  • 12. Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices.
    Raptis A, Duh MS, Wang ST, Dial E, Fanourgiakis I, Fortner B, Paley C, Mody-Patel N, Corral M, Scott J.
    Transfusion; 2010 Jan 14; 50(1):190-9. PubMed ID: 19719471
    [Abstract] [Full Text] [Related]

  • 13. Red Blood Cell Transfusion Dependency and Hyperferritinemia Are Associated with Impaired Survival in Patients Diagnosed with Myelodysplastic Syndromes: Results from the First Polish MDS-PALG Registry.
    Waszczuk-Gajda A, Mądry K, Machowicz R, Drozd-Sokołowska J, Stella-Hołowiecka B, Mital A, Obara A, Szmigielska-Kapłon A, Sikorska A, Subocz E, Jędrzejczak WW, Dwilewicz-Trojaczek J.
    Adv Clin Exp Med; 2016 Jan 14; 25(4):633-41. PubMed ID: 27629836
    [Abstract] [Full Text] [Related]

  • 14. Can iron overload in patients with lower-risk myelodysplastic syndromes be reduced using erythropoiesis-stimulating agents?
    Tsang E, Leitch HA.
    Ann Hematol; 2016 Jan 14; 95(1):73-78. PubMed ID: 26453076
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Evolution of iron overload in patients with low-risk myelodysplastic syndrome: iron chelation therapy and organ complications.
    Remacha ÁF, Arrizabalaga B, Villegas A, Durán MS, Hermosín L, de Paz R, Garcia M, Diez Campelo M, Sanz G, IRON-2 Study Group.
    Ann Hematol; 2015 May 14; 94(5):779-87. PubMed ID: 25516455
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome.
    Shenoy N, Vallumsetla N, Rachmilewitz E, Verma A, Ginzburg Y.
    Blood; 2014 Aug 07; 124(6):873-81. PubMed ID: 24923296
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes.
    Delforge M, Selleslag D, Triffet A, Mineur P, Bries G, Graux C, Trullemans F, MacDonald K, Abraham I, Pluymers W, Ravoet C.
    Ann Hematol; 2011 Jun 07; 90(6):655-66. PubMed ID: 21318574
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.